PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
Go Deep

Aurobindo Pharma Limited

Aurobindo Pharma Limited Score & Ratio Trend

DateScoreP/EP/BD/EPrice
Oct 2026 21,897 26.0 2.53 0.21 1,666.90

Aurobindo Pharma Limited Quarterly Results

Line Item Jun 2026Mar 2026Dec 2025Jun 2025
Revenue 91,058,200,000.0 87,515,000,000.0 86,045,100,000.0 77,917,700,000.0
Net Profit 10,325,600,000.0 9,212,600,000.0 9,102,900,000.0 8,247,500,000.0
EPS 17.9 15.9 15.7 14.2

Aurobindo Pharma Limited Revenue & Profit: Last 5 Years

Line Item Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Revenue 333,847,400,000.0 313,781,300,000.0 287,045,000,000.0 246,171,300,000.0 —
Net Profit 35,047,500,000.0 34,858,800,000.0 31,729,700,000.0 19,275,000,000.0 —
EPS 60.3 59.8 54.2 32.9 —

Aurobindo Pharma Limited Balance Sheet

Line Item Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Total Assets 585,021,500,000.0 497,849,700,000.0 450,715,100,000.0 398,899,900,000.0 —
Total Liabilities 206,193,400,000.0 171,380,400,000.0 152,207,100,000.0 130,381,400,000.0 —
Total Equity 378,909,700,000.0 326,533,200,000.0 298,428,000,000.0 268,398,500,000.0 —

Owes vs Owns

Aurobindo Pharma Limited owed ₹0.35 for every ₹1 it owned in Mar 2026, up from ₹0.33 in Mar 2023.

PeriodMar 2026Mar 2025Mar 2024Mar 2023
Owes vs Owns 0.35× 0.34× 0.34× 0.33×

Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.

Aurobindo Pharma Limited Assets & Liabilities Breakdown (₹ Cr)

What it owns — Mar 2026

Cash & short-term investments 18.1%Receivables 12.1%Inventory 20.6%Fixed assets (tangible) 30.1%Intangible assets 9.0%Other assets 9.7%

How it's funded — Mar 2026

Short-term debt 11.7%Long-term debt 1.4%Payables 9.5%Other liabilities 12.6%Shareholders' equity 64.8%
Line Item Mar 2026Mar 2025Mar 2024Mar 2023
Assets
Cash & short-term investments10,579.48,198.66,325.26,223.6
Receivables7,094.45,745.94,816.74,466.4
Inventory12,052.910,543.79,808.28,511.2
Fixed assets (tangible)17,609.015,634.014,411.712,803.6
Intangible assets5,281.44,238.74,076.63,921.9
Long-term investments198.0133.5170.1168.4
Other assets5,687.25,290.55,463.03,794.9
Liabilities & equity
Short-term debt6,873.46,380.04,180.34,242.6
Long-term debt802.81,561.72,134.9619.0
Payables5,567.34,188.94,454.23,871.3
Other liabilities7,375.95,007.54,451.34,305.3
Shareholders' equity37,882.832,646.929,850.826,851.8
Net tangible assets32,609.628,414.625,766.222,917.9

Aurobindo Pharma Limited Cash Flow

Line Item Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Operating Activities 55,263,700,000.0 39,246,200,000.0 24,345,200,000.0 23,867,500,000.0 —
Investing Activities -34,586,100,000.0 -18,758,000,000.0 -42,559,500,000.0 -39,777,500,000.0 —
Financing Activities -12,691,500,000.0 1,197,800,000.0 8,004,200,000.0 18,144,100,000.0 —

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.